|Mr. Sanj K. Patel||CEO & Chairman||1.25M||N/A||1970|
|Dr. John F. Paolini||Sr. VP & Chief Medical Officer||593.88k||N/A||1965|
|Mr. Qasim Rizvi M.B.A.||Sr. VP of Operations & Chief Commercial Officer||920.3k||N/A||1970|
|Mr. Michael R. Megna||Principal Financial Officer & Chief Accounting Officer||N/A||N/A||1971|
|Mr. Thomas W. Beetham||Exec. VP of Corp. Devel. & Operations, Chief Legal Officer and Sec.||N/A||N/A||1970|
|Mr. Dave Nichols||Sr. VP of Technical Operations||N/A||N/A||N/A|
|Mark Ragosa C.F.A.||VP of Investor Relations||N/A||N/A||N/A|
|Ms. Melissa Manno||VP of HR||N/A||N/A||N/A|
|Mr. Rasmus Holm-Jorgensen||Sr. VP, Chief Strategy & Portfolio Officer||N/A||N/A||N/A|
|Mr. Carsten Boess||Exec. VP of Corp. Affairs||N/A||N/A||1967|
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and in Phase 1a clinical trial for the treatment of atopic dermatitis. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate investigational combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.
Kiniksa Pharmaceuticals, Ltd.’s ISS Governance QualityScore as of October 6, 2020 is 10. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 10; Compensation: 7.